RxDoctor Payments Data

Cassandra Barnes

Family Medicine · Atlanta, GANPI 1871027870

Payments from drug & device makers

$10,209in general payments, 2019–2025

Across 527 payments — averaging $19.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novo Nordisk$2K
  • AstraZeneca$462
  • Astellas Pharma US Inc$371
  • Inspire Medical Systems, Inc.$363
  • Amgen$361
  • plus $4K from 45 others

What the payments were for

  • Food & beverage$10,164100%
  • Education$450%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,209 in reported general payments places this provider in the 90th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$45,400
Medicare patients
92
Services billed
608

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide19$20,037
OzempicSemaglutide12$13,578
BelsomraSuvorexant11$6,469
Rosuvastatin Calcium156$1,851
Levothyroxine Sodium99$911
Atorvastatin Calcium111$892
Estradiol15$868
Escitalopram Oxalate64$865
Trazodone Hcl85$844
Gabapentin35$797
Mirtazapine27$769
Fluticasone Propionate55$621
Liothyronine Sodium11$490
ValacyclovirValacyclovir Hcl18$482
Omeprazole43$440

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$330$20,03719 claims
Novo NordiskOzempic$1,557$13,57812 claims
MerckBelsomra$17$6,46911 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$53$91199 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Atlanta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →